Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MANNITOL 5 W DEXTROSE 5 IN SODIUM CHLORIDE 0 12.
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MANNITOL 5 W DEXTROSE 5 IN SODIUM CHLORIDE 0 12.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from extravascular spaces (e.g., brain, eyes) into the intravascular compartment and enhancing water excretion by the kidneys. Dextrose provides caloric supplementation, and sodium chloride provides electrolytes to maintain tonicity.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion. For osmotic diuresis: 50-100 g (1000-2000 mL of this solution) over 1-2 hours, total dose not exceeding 200 g/day. For reduction of intracranial pressure: 1.5-2 g/kg as a 20-25% solution given IV over 30-60 minutes. This 5% solution is not typically used for ICP reduction due to dilution.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Mannitol: 0.25–1.5 hours (approximately 15–90 minutes); prolonged in renal impairment. Dextrose: <30 minutes (endogenous regulation).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% mannitol excreted unchanged in urine; dextrose is fully reabsorbed or metabolized; sodium chloride is handled by renal tubules.
Category C
Category A/B
Electrolyte
Electrolyte